Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613626 · ClinicalTrials.gov registry record · Phase 2
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00613626 is a Phase 2 study that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 74 participants.
The verdict
NCT00613626, a Phase 2 study, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.
Interventions
- DRUG Placebo
- DRUG Cisplatin
- DRUG Etoposide
- DRUG ZD6474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2008-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613626
The ClinicalTrials.gov registry entry for NCT00613626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00613626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00613626 about?
NCT00613626 is a clinical study titled "Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer". At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in t...
What is the current status of trial NCT00613626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2008-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00613626?
The interventions under investigation include: Placebo (DRUG), Cisplatin (DRUG), Etoposide (DRUG), ZD6474 (DRUG).
Who is sponsoring clinical trial NCT00613626?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.